摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-amino-N-[(1-butyl-4-piperidinyl)methyl]-5-chloro-2-methoxybenzamide

中文名称
——
中文别名
——
英文名称
4-amino-N-[(1-butyl-4-piperidinyl)methyl]-5-chloro-2-methoxybenzamide
英文别名
4-amino-N-[(1-butylpiperidin-4-yl)methyl]-5-chloro-2-methoxybenzamide
4-amino-N-[(1-butyl-4-piperidinyl)methyl]-5-chloro-2-methoxybenzamide化学式
CAS
——
化学式
C18H28ClN3O2
mdl
——
分子量
353.892
InChiKey
ZHSYLOVCWQPBJK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    24
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.61
  • 拓扑面积:
    67.6
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
    申请人:——
    公开号:US20020086879A1
    公开(公告)日:2002-07-04
    The present invention of compounds of formula (I) 1 a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R 1 and R 2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C 1-6 alkyl; R 3 is hydrogen or halo; R 4 is hydrogen or C 1-6 alkyl; R 5 is hydrogen or C 1-6 alkyl; L is C 3-6 cycloalkyl, C 5-6 cycloalkanone, C 2-6 alkenyl, or L is a radical of formula —Alk—R 6 —, Alk—X—R 7 , —Alk—Y—C(═O)—R 9 , or —Alk—Y—C(═O)— NR 11 R 12 wherein each Alk is C 1-12 alkanediyl; and R 6 is hydrogen, cyano, C 1-6 alkylsulfonylamino, C 3-6 cycloalkyl, C 5-6 cycloalkanone, or a heterocyclic ringsystem; R 7 is hydrogen, C 1-6 alkyl, hydroxyC 1-6 alkyl, C 3-6 cycloalkyl, or a heterocyclic ringsystem; X is O, SO 2 or NR 8 ; said R 8 being hydrogen or C 1-6 alkyl; R 9 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy or hydroxy; Y is NR 10 or a direct bond; said R 10 being hydrogen, or C 1-6 alkyl; R 11 and R 12 each independently are hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, or R 11 and R 12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
    本发明涉及化合物的一种以及其立体化学异构体形式,N-氧化物形式或药学上可接受的酸加合物盐,其中R1和R2结合在一起形成以下式的二价基团,其中在所述二价基团中一个或两个氢原子可被C1-6烷基取代;R3为氢或卤素;R4为氢或C1-6烷基;R5为氢或C1-6烷基;L为C3-6环烷基,C5-6环戊酮,C2-6烯基,或L为以下式的基团—Alk—R6—,Alk—X—R7,—Alk—Y—C(═O)—R9或—Alk—Y—C(═O)—NR11R12,其中每个Alk为C1-12烷二基;R6为氢,氰基,C1-6烷基磺酰氨基,C3-6环烷基,C5-6环戊酮或杂环环系;R7为氢,C1-6烷基,羟基C1-6烷基,C3-6环烷基或杂环环系;X为O,SO2或NR8;R8为氢或C1-6烷基;R9为氢,C1-6烷基,C3-6环烷基,C1-6烷氧基或羟基;Y为NR10或直接键;R10为氢或C1-6烷基;R11和R12各自独立地为氢,C1-6烷基,C3-6环烷基,或R11和R12与氮原子结合可形成可选择取代的吡咯烷基,哌啶基,哌嗪基或4-吗啉基环。公开了制备所述产品的过程,包括所述产品的制剂以及它们作为药物的用途,特别用于治疗与胃排空障碍有关的病症。
  • Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
    申请人:——
    公开号:US20030078427A1
    公开(公告)日:2003-04-24
    The present invention of compounds of formula (I) 1 a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R 1 is C 1-6 alkyloxy, C 2-6 alkenyloxy or C 2-6 alkynyl-oxy; R 2 is hydrogen, C 1-6 alkyl C 1-6 alkyloxy; R 3 is hydrogen or halo; R 4 is hydrogen or C 1-6 alkyl; R 5 is hydrogen or C 1-6 alkyl; L is C 3-6 cycloalkyl, C 5-6 cycloalkanone, C 2-6 alkenyl, or L is a radical of formula-Alk-R 6 —, Alk-X—R 7 , —Alk-Y—C(═O)—R 9 , or —Alk-Y—C(═O)—NR 11 R 12 wherein each Alk is C 1-12 alkanediyl; and R 6 is hydrogen, cyano, C 1-6 alkylsulfonylamino, C 3-6 cycloalkyl, C 5-6 cyclo-alkanone, or a heterocyclic ringsystem; R 7 is hydrogen, C 1-6 alkyl, hydroxyC 1-6 alkyl, C 3-6 cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO 2 or NR 8 ; said R 8 being hydrogen or C 1-6 alkyl; R 9 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy or hydroxy; Y is NR 10 or a direct bond; said R 10 being hydrogen, or C 1-6 alkyl; R 11 and R 12 each independently are hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, or R 11 and R 12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
    本发明涉及式(I)化合物,其立体化学异构体形式,其N-氧化物形式或其药学上可接受的酸加成盐,其中R1为C1-6烷氧基,C2-6烯氧基或C2-6炔氧基;R2为氢,C1-6烷基或C1-6烷氧基;R3为氢或卤素;R4为氢或C1-6烷基;R5为氢或C1-6烷基;L为C3-6环烷基,C5-6环戊酮,C2-6烯基,或L为式-Alk-R6—,Alk-X—R7,—Alk-Y—C(═O)—R9或—Alk-Y—C(═O)—NR11R12的基团,其中每个Alk为C1-12烷二基;R6为氢,氰基,C1-6烷基磺酰氨基,C3-6环烷基,C5-6环戊酮或杂环环系;R7为氢,C1-6烷基,羟基C1-6烷基,C3-6环烷基或杂环环系;X为O,S,SO2或NR8;其中R8为氢或C1-6烷基;R9为氢,C1-6烷基,C3-6环烷基,C1-6烷氧基或羟基;Y为NR10或直接键;其中R10为氢或C1-6烷基;R11和R12各自独立地为氢,C1-6烷基,C3-6环烷基,或R11和R12与氮原子结合可以形成可选择取代的吡咯烷基,哌啶基,哌嗪基或4-吗啉基环。公开了制备所述产品的过程,包含所述产品的配方以及其作为药物的用途,特别是用于治疗与胃排空障碍有关的疾病。
  • Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives
    申请人:Bosmans Jean-Paul René Marie André
    公开号:US20100210657A1
    公开(公告)日:2010-08-19
    The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
    本发明涉及式(I)化合物,其立体化学异构体形式,N-氧化物形式或药学上可接受的酸加盐形式。公开了制备上述产品的过程,包括含有该产品的制剂以及其作为药物的用途,特别是用于治疗与胃排空障碍相关的疾病。
  • Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives
    申请人:Bosmans Jean-Paul René Marie André
    公开号:US20120028987A1
    公开(公告)日:2012-02-02
    The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
    本发明涉及式(I)化合物及其立体化学异构体、N-氧化物形式或药学上可接受的酸加成盐。公开了制备上述产品的过程、包含上述产品的配方以及它们作为药物的用途,特别是用于治疗与胃排空障碍有关的疾病。
  • Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)- piperdine derivatives
    申请人:JANSSEN PHARMACEUTICA N.V.
    公开号:EP1206938A1
    公开(公告)日:2002-05-22
    The present invention of compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 and R2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl; R3 is hydrogen or halo; R4 is hydrogen or C1-6alkyl; R5 is hydrogen or C1-6alkyl; L is C3-6cycloalkyl, C5-6cycloalkanone, C2-6alkenyl, or L is a radical of formula -Alk-R6-, Alk-X-R7, -Alk-Y-C(=O)-R9 , or -Alk-Y-C(=O)-NR11R12 wherein each Alk is C1-12alkanediyl; and R6 is hydrogen, cyano, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cycloalkanone, or a heterocyclic ringsystem; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6alkyl; R9 is hydrogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy or hydroxy; Y is NR10 or a direct bond; said R10 being hydrogen, or C1-6alkyl; R11 and R12 each independently are hydrogen, C1-6alkyl, C3-6cycloalkyl, or R11 and R12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
    本发明的式(I)化合物 其立体化学异构形式、其 N-氧化物形式或其药学上可接受的酸加成盐,R1 和 R2 共同形成式中的二价基,其中所述二价基中的一个或两个氢原子可被 C1-6 烷基取代;R3 是氢或卤代; R4 是氢或 C1-6烷基; R5 是氢或 C1-6烷基; L 是 C3-6环烷基、C5-6环烷基酮、C2-6烯基,或 L 是式-Alk-R6-、Alk-X-R7、-Alk-Y-C(=O)-R9 或-Alk-Y-C(=O)-NR11R12 的基,其中每个 Alk 是 C1-12 烷二基;R6是氢、氰基、C1-6烷基磺酰氨基、C3-6环烷基、C5-6环烷基酮或杂环环烷;R7是氢、C1-6烷基、羟基C1-6烷基、C3-6环烷基或杂环环烷;X是O、S、SO2或NR8;所述R8是氢或C1-6烷基;R9是氢、C1-6烷基、C3-6环烷基、C1-6烷氧基或羟基;Y 是 NR10 或直接键;所述 R10 是氢或 C1-6 烷基;R11 和 R12 各自独立地是氢、C1-6 烷基、C3-6 环烷基,或 R11 和 R12 与氮原子结合可形成任选取代的吡咯烷基、哌啶基、哌嗪基或 4-吗啉基环。公开了制备上述产品的工艺、包含上述产品的制剂及其作为药物的用途,特别是用于治疗与胃排空障碍有关的疾病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐